Form 4 for MNPR Monopar Therapeutics
Accepted 2025-07-16 00:00:00 ET · period of report 2025-07-14 · accession 0001437749-25-022863 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-16 | 2025-07-14 | MNPR | Tsuchimoto Kim R | Dir | X - OptEx | $0.01 | +8,904 | 20.4K | +78% | +$89.04 |
| D | 2025-07-16 | 2025-07-14 | MNPR | Tsuchimoto Kim R | Dir | S - Sale+OE | $40.00 | -8,904 | 11.5K | -44% | -$356.2K |
| DM | 2025-07-16 | 2025-07-14 | MNPR | Tsuchimoto Kim R | Dir | X - OptEx | $0.00 | -8,904 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-14 | X | A | 8,904 | $0.01 | 20,390 | D | — | — | (F1) This transaction involved a cash exercise of stock options. |
| 2 | Common | Common Stock | 2025-07-14 | S | D | 8,904 | $40.00 | 11,486 | D | — | — | (F2) The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. |
| 3 | Derivative | Stock Options | 2025-07-14 | X | D | 4,200 | $0.00 | 0 | D | $0.01 · — to 2026-04-04 | 4,200 Common Stock | (F3) Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter. |
| 4 | Derivative | Stock Options | 2025-07-14 | X | D | 4,704 | $0.00 | 0 | D | $0.01 · — to 2027-02-20 | 4,704 Common Stock | (F4) Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter. |